Juniper Pharmaceuticals (Nasdaq: JNP) address unmet and underserved medical needs in women's health. Our product pipeline leverages our highly differentiated intravaginal ring ("IVR") technology, which we expect will offer multiple benefits to patients. Current 505(b)(2) candidates include:
- JNP-0101, an oxybutynin IVR for the treatment of overactive bladder in women;
- JNP-0201, a combination estradiol + progesterone IVR for hormone replacement therapy; and,
- JNP-0301, a natural progesterone IVR for the prevention of preterm birth.
Our R&D programs are supported by cash flow generated by Crinone® (progest More >>